Clinical Trial Update: A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment [NA]

View source ↗

Summary

A completed clinical trial evaluating tolerability and efficacy of AKST1210 in patients on hemodialysis with cognitive impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• End-stage Renal Disease

Drugs mentioned

• AKST1210

Snippet

Sponsor: Alkahest, Inc. | Conditions: Cognitive Impairment, End Stage Renal Disease | NA | Status: COMPLETED | Results posted: 2022-12-12